{
    "clinical_study": {
        "@rank": "161517", 
        "arm_group": [
            {
                "arm_group_label": "MCV-ACYW135 Vaccine Group", 
                "arm_group_type": "Experimental", 
                "description": "Participants at age 2 to 6 years of enrollment will receive 1 doses on Meningococcal ( A, C, Y and W 135)  conjugate vaccine.\nParticipants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135)  conjugate vaccine at 3 months apart.\nParticipants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135)  conjugate vaccine at 1 months apart.\nParticipants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135)  conjugate vaccine at 2 months apart."
            }, 
            {
                "arm_group_label": "MPV-ACYW135 Vaccine Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants at age 2 to 6 years of enrollment will receive 1 doses on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine"
            }, 
            {
                "arm_group_label": "MPV-A Vaccine Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart."
            }, 
            {
                "arm_group_label": "MCV-AC Vaccine Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 months apart."
            }, 
            {
                "arm_group_label": "Hib Vaccine Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this observer-blind study is to evaluate the safety, reactogenicity and\n      immunogenicity of Meninggococcal (A,C,Y and W135) Conjugate Vaccine in 2 months to 6\n      years-old children."
        }, 
        "brief_title": "Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningitis", 
        "condition_browse": {
            "mesh_term": "Meningitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes will comply with the requirements of the\n             protocol should be enrolled in the study.\n\n          -  Healthy permanent residence 2 months to 6 years old.\n\n          -  Subjects and parent/guardian able to attend all scheduled visits and comply with all\n             study procedures.\n\n          -  Axillary temperature \u226437.0 \u2103.\n\n        Exclusion Criteria:\n\n          -  History of meningitis infection or vaccination of meningococcal vaccine within the\n             past 6 months.\n\n          -  Allergic history or any SAE after vaccination, such as allergy, urticaria, dyspnea,\n             angioedema, celialgia.\n\n          -  Patients administered with immunosuppressive agents, cytotoxicity factor or\n             corticosteroids in the 6 months preceding the vaccine trial.\n\n          -  Receipt of blood or blood-derived products in the 3 months preceding vaccination\n\n          -  Participation in another clinical study investigating a vaccine, drug in the 30 days\n             preceding vaccination.\n\n          -  Receipt of any live virus vaccine in the 15 days preceding vaccination.\n\n          -  Receipt of any subunit vaccine and inactivated vaccine in the 7 days before\n             vaccination.\n\n          -  Febrile illness (temperature \u2265 38\u00b0C) in the 3 days or any acute illness/infection in\n             the 7 days preceding vaccination.\n\n          -  Thrombocytopenia.\n\n          -  History of thyroid gland excision or treatment for thyroid gland disease in last 12\n             months.\n\n          -  Functional or anatomic asplenia.\n\n          -  History of eclampsia, epilepsy, encephalopathy and mental disease or family disease.\n\n          -  Chronic disease (such as Down syndrome, diabetes, sickle cell anemia or neurologic\n             disease, Guillain-Barre Syndrome).\n\n          -  Known or suspected diseases, including: respiratory system disease, acute infection\n             or active stage of chronic disease, HIV infection of children or mothers,\n             cardiovascular disease, acute hypertension, cancer treatment, skin disease, etc.\n\n          -  Any condition that, in the judgment of investigator, may affect trial assessment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "2195", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003495", 
            "org_study_id": "2013L01041", 
            "secondary_id": "2013L01041"
        }, 
        "intervention": [
            {
                "arm_group_label": "MCV-ACYW135 Vaccine Group", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "MCV-ACYW135 Vaccine Group", 
                "intervention_type": "Biological", 
                "other_name": "Meningococcal ( A, C, Y and W 135) conjugate vaccine"
            }, 
            {
                "arm_group_label": "MPV-ACYW135 Vaccine Group", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "MPV-ACYW135 Vaccine Group", 
                "intervention_type": "Biological", 
                "other_name": "Group A, C, Y and W-135 Meningococcal Polysaccharide Vaccine"
            }, 
            {
                "arm_group_label": "MPV-A Vaccine Group", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "MPV-A Vaccine Group", 
                "intervention_type": "Biological", 
                "other_name": "Group A Meningococcal Polysaccharide vaccine"
            }, 
            {
                "arm_group_label": "MCV-AC Vaccine Group", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "MCV-AC Vaccine Group", 
                "intervention_type": "Biological", 
                "other_name": "Group A and C Meningococcal conjugate vaccine"
            }, 
            {
                "arm_group_label": "Hib Vaccine Group", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "Hib Vaccine Group", 
                "intervention_type": "Biological", 
                "other_name": "Haemophilus Influenzae Type b Conjugate Vaccine"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Immunogenicity, Safety, Meningococcal Conjugate Vaccine", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "xiasl@hncdc.com.cn", 
                "last_name": "shengli xia", 
                "phone": "86-371-68089128"
            }, 
            "facility": {
                "address": {
                    "city": "Zhengzhou", 
                    "country": "China", 
                    "state": "Henan"
                }, 
                "name": "Center of henan province for Disease Control and Prevention"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "5", 
        "official_title": "Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine in Healthy Subjects 2 Months to 6 Years of Age in China", 
        "overall_contact": {
            "email": "guifan@sohu.com", 
            "last_name": "Guifan Li", 
            "phone": "86-10-59613591"
        }, 
        "overall_official": {
            "affiliation": "center of Henan province for disease control and prevention", 
            "last_name": "shengli xia", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects exhibiting a >= 4fold increase in rSBA titers level from pre-vaccination to post-vaccination", 
            "safety_issue": "No", 
            "time_frame": "28 days after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003495"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "to evaluate the adverse reactions after vaccination", 
            "safety_issue": "Yes", 
            "time_frame": "28 days after vaccination"
        }, 
        "source": "Beijing Minhai Biotechnology Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Minhai Biotechnology Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}